Sarepta Therapeutics, Inc.
Exon skipping oligomer conjugates for muscular dystrophy
Last updated:
Abstract:
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
Status:
Grant
Type:
Utility
Filling date:
24 Jul 2020
Issue date:
24 May 2022